Basilea announces distribution agreement with Avir Pharma Inc.

Wednesday, Jun 14, 2017

Basilea Pharmaceutica Ltd. announced today that Basilea Pharmaceutica International Ltd. has entered into a distribution and license agreement with Avir Pharma Inc. (Avir) for Basilea's antifungal Cresemba® (isavuconazole) and antibiotic Zevtera® (ceftobiprole) in Canada.

Under the terms of the agreement, Avir is granted an exclusive license to commercialize isavuconazole and ceftobiprole in the Canadian market. Basilea will receive an upfront payment and is eligible to receive milestone payments upon achievement of regulatory and commercial milestones. Avir plans to apply for a marketing authorization for isavuconazole in Canada. Zevtera is already approved by Health Canada for the treatment of adult patients with hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), and for the treatment of community-acquired pneumonia (CAP). Avir will be purchasing product from Basilea and be responsible for commercialization in Canada.

David Veitch, Basilea's Chief Commercial Officer, stated: "Cresemba and Zevtera are clearly differentiated hospital products potentially addressing significant medical needs of patients who are suffering from severe microbial infections. We look forward to bringing our products to patients in Canada through our partnership with Avir which has a strong presence in the specialty care market."



Other News